Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 42.79 Million USD | -37.4% |
| 2022 | 68.35 Million USD | -36.68% |
| 2021 | 107.95 Million USD | 191.38% |
| 2020 | 37.04 Million USD | 340.98% |
| 2019 | -15.37 Million USD | -673.66% |
| 2018 | 2.68 Million USD | 178.43% |
| 2017 | -3.41 Million USD | 70.23% |
| 2016 | -11.47 Million USD | 58.69% |
| 2015 | -27.78 Million USD | 58.03% |
| 2014 | -66.2 Million USD | -1492.68% |
| 2013 | -4.15 Million USD | 60.3% |
| 2012 | -10.47 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 41.72 Million USD | -2.5% |
| 2024 Q2 | 42.7 Million USD | 2.35% |
| 2023 FY | 42.79 Million USD | -37.4% |
| 2023 Q2 | 23.31 Million USD | -57.5% |
| 2023 Q3 | 41.38 Million USD | 77.52% |
| 2023 Q4 | 42.79 Million USD | 3.41% |
| 2023 Q1 | 54.85 Million USD | -19.76% |
| 2022 Q4 | 68.35 Million USD | -10.05% |
| 2022 Q2 | 105.85 Million USD | -9.99% |
| 2022 Q1 | 117.6 Million USD | 8.94% |
| 2022 FY | 68.35 Million USD | -36.68% |
| 2022 Q3 | 75.99 Million USD | -28.2% |
| 2021 Q2 | 31.16 Million USD | -25.19% |
| 2021 Q1 | 41.65 Million USD | 12.44% |
| 2021 Q3 | 87.75 Million USD | 181.61% |
| 2021 Q4 | 107.95 Million USD | 23.01% |
| 2021 FY | 107.95 Million USD | 191.38% |
| 2020 FY | 37.04 Million USD | 340.98% |
| 2020 Q3 | -30.48 Million USD | 58.8% |
| 2020 Q4 | 37.04 Million USD | 221.51% |
| 2020 Q2 | -74 Million USD | -768.66% |
| 2020 Q1 | -8.51 Million USD | 44.59% |
| 2019 Q4 | -15.37 Million USD | 51.56% |
| 2019 Q2 | -50.09 Million USD | -1189.58% |
| 2019 Q1 | 4.59 Million USD | 71.57% |
| 2019 FY | -15.37 Million USD | -673.66% |
| 2019 Q3 | -31.73 Million USD | 36.65% |
| 2018 Q2 | -22.78 Million USD | -353.13% |
| 2018 Q3 | -12.07 Million USD | 47.01% |
| 2018 Q4 | 2.68 Million USD | 122.19% |
| 2018 FY | 2.68 Million USD | 178.43% |
| 2018 Q1 | -5.02 Million USD | -47.18% |
| 2017 FY | -3.41 Million USD | 70.23% |
| 2017 Q4 | -3.41 Million USD | 40.58% |
| 2017 Q3 | -5.75 Million USD | 24.22% |
| 2017 Q2 | -7.58 Million USD | 22.17% |
| 2017 Q1 | -9.74 Million USD | 15.06% |
| 2016 FY | -11.47 Million USD | 58.69% |
| 2016 Q1 | -20.15 Million USD | 27.48% |
| 2016 Q4 | -11.47 Million USD | 20.09% |
| 2016 Q3 | -14.36 Million USD | 17.79% |
| 2016 Q2 | -17.47 Million USD | 13.29% |
| 2015 Q1 | -60.93 Million USD | 7.97% |
| 2015 Q3 | -41.36 Million USD | 22.11% |
| 2015 Q4 | -27.78 Million USD | 32.83% |
| 2015 FY | -27.78 Million USD | 58.03% |
| 2015 Q2 | -53.1 Million USD | 12.84% |
| 2014 Q3 | -10.75 Million USD | 0.0% |
| 2014 FY | -66.2 Million USD | -1492.68% |
| 2014 Q4 | -66.2 Million USD | -515.85% |
| 2013 FY | -4.15 Million USD | 60.3% |
| 2013 Q4 | -4.15 Million USD | 0.0% |
| 2012 FY | -10.47 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 3266741.221% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -657.617% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 17243.258% |
| Rebus Holdings, Inc. | 305 Thousand USD | -13930.492% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 778.767% |
| Qrons Inc. | 351.42 Thousand USD | -12076.924% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -6775.88% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 1.476% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 209787.377% |
| Skye Bioscience, Inc. | -5.72 Million USD | 847.948% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -171.478% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -939.163% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -10549.025% |
| SQZ Biotechnologies Company | -36.23 Million USD | 218.089% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -1808.499% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -4515.363% |
| Mesoblast Limited | 55.85 Million USD | 23.39% |
| Marizyme, Inc. | 18.56 Million USD | -130.454% |
| Genus plc | 190.6 Million USD | 77.548% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -1813.963% |
| Pharming Group N.V. | 109.8 Million USD | 61.028% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -4874.536% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -3425.284% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -6193.088% |
| ContraFect Corporation | -6.02 Million USD | 810.139% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -31683.51% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -3603.646% |
| IMV Inc. | 7.67 Million USD | -457.889% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -677.786% |
| MultiCell Technologies, Inc. | 90.04 USD | -47526554.82% |
| ONE Bio Corp. | 9.04 Million USD | -373.372% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 5930.284% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -230.55% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -3028.21% |
| Q BioMed Inc. | 4.06 Million USD | -954.013% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -40.057% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -4146.534% |
| Biomind Labs Inc. | 711.4 Thousand USD | -5915.305% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 29.321% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -2040.301% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -234.148% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11796.528% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -30509.282% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -215297.393% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1843.386% |
| GB Sciences, Inc. | 1.74 Million USD | -2349.07% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 23383.892% |
| HST Global, Inc. | 96.79 Thousand USD | -44110.842% |
| CSL Limited | 10.52 Billion USD | 99.593% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -20651.441% |
| Halberd Corporation | 144.72 Thousand USD | -29469.309% |
| Enzolytics Inc. | 981.65 Thousand USD | -4259.266% |
| Agentix Corp. | 37.63 Thousand USD | -113617.414% |
| Resverlogix Corp. | 6.45 Million USD | -563.355% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 6457.703% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 102.109% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 191.026% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -505.193% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1479.885% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 584.089% |
| AVAX Technologies, Inc. | -5.9 Million USD | 824.911% |
| Zenith Capital Corp. | 10.06 Thousand USD | -425108.665% |
| Genscript Biotech Corporation | -1.06 Billion USD | 104.032% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -21250.383% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -1693.478% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -25912.559% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 233711.748% |
| Kadimastem Ltd | -253.1 Thousand USD | 17007.413% |
| Helix BioMedix, Inc. | -2.57 Million USD | 1765.077% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -111.052% |
| BioStem Technologies, Inc. | 4.47 Million USD | -856.907% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -21163.18% |
| LadRx Corporation | -2.03 Million USD | 2201.333% |
| Cell Source, Inc. | 9.23 Million USD | -363.53% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6637.283% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6637.283% |
| NovAccess Global Inc. | 2.17 Million USD | -1864.365% |
| Affymax, Inc. | -5.59 Million USD | 864.57% |
| Itoco Inc. | 228.3 Thousand USD | -18643.786% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -31367.986% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -763.284% |
| Mobile Lads Corp. | 484.23 Thousand USD | -8737.293% |
| CytoDyn Inc. | 20.26 Million USD | -111.198% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 6614164.915% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 461811.59% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -455.32% |
| SYBLEU INC | 473.71 Thousand USD | -8933.51% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -860.125% |
| International Stem Cell Corporation | 2.59 Million USD | -1552.239% |
| Bioxytran, Inc. | 1.89 Million USD | -2153.551% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -68464.241% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1862.172% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1146.156% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -400.327% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -5438.78% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 3523.44% |
| Neutra Corp. | 52.18 Thousand USD | -81899.348% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 1819.285% |
| PureTech Health plc | -167.19 Million USD | 125.594% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 17573.092% |
| IXICO plc | -4.44 Million USD | 1062.812% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -223.723% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 21.983% |
| CSL Limited | 10.52 Billion USD | 99.593% |
| Cellectis S.A. | -43.81 Million USD | 197.659% |